Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

BioSpecifics Technologies

Nasdaq:BSTC
Snowflake Description

Flawless balance sheet and slightly overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
BSTC
Nasdaq
$378M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for various indications in the United States and internationally. The last earnings update was 12 days ago. More info.


Add to Portfolio Compare Print
  • BioSpecifics Technologies has significant price volatility in the past 3 months.
BSTC Share Price and Events
7 Day Returns
15.8%
NasdaqGM:BSTC
6.3%
US Biotechs
12.6%
US Market
1 Year Returns
-17.4%
NasdaqGM:BSTC
1.6%
US Biotechs
-9.1%
US Market
BSTC Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
BioSpecifics Technologies (BSTC) 15.8% -11.2% -9.6% -17.4% -6% 32.1%
US Biotechs 6.3% -7.9% -7.9% 1.6% 7.7% -8.8%
US Market 12.6% -16.7% -19.6% -9.1% 8.2% 21.5%
1 Year Return vs Industry and Market
  • BSTC underperformed the Biotechs industry which returned 1.6% over the past year.
  • BSTC underperformed the Market in United States of America which returned -9.1% over the past year.
Price Volatility
BSTC
Industry
5yr Volatility vs Market
Related Companies

BSTC Value

 Is BioSpecifics Technologies undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of BioSpecifics Technologies to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for BioSpecifics Technologies.

NasdaqGM:BSTC Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 1 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 7.9%
Perpetual Growth Rate 10-Year US Government Bond Rate 1.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqGM:BSTC
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 1.7%
Equity Risk Premium S&P Global 5.4%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.2
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.203 (1 + (1- 21%) (0.06%))
1.136
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.14
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 1.74% + (1.136 * 5.44%)
7.92%

Discounted Cash Flow Calculation for NasdaqGM:BSTC using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for BioSpecifics Technologies is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

NasdaqGM:BSTC DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 7.92%)
2020 25.67 Est @ 15.19% 23.79
2021 28.53 Est @ 11.16% 24.50
2022 30.91 Est @ 8.33% 24.59
2023 32.88 Est @ 6.35% 24.24
2024 34.51 Est @ 4.97% 23.57
2025 35.89 Est @ 4% 22.72
2026 37.08 Est @ 3.32% 21.75
2027 38.14 Est @ 2.85% 20.73
2028 39.10 Est @ 2.52% 19.69
2029 39.99 Est @ 2.28% 18.66
Present value of next 10 years cash flows $224.00
NasdaqGM:BSTC DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $39.99 × (1 + 1.74%) ÷ (7.92% – 1.74%)
$658.28
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $658.28 ÷ (1 + 7.92%)10
$307.16
NasdaqGM:BSTC Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $224.00 + $307.16
$531.16
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $531.16 / 7.34
$72.4
NasdaqGM:BSTC Discount to Share Price
Calculation Result
Value per share (USD) From above. $72.40
Current discount Discount to share price of $51.50
= -1 x ($51.50 - $72.40) / $72.40
28.9%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price BioSpecifics Technologies is available for.
Intrinsic value
29%
Share price is $51.5 vs Future cash flow value of $72.4
Current Discount Checks
For BioSpecifics Technologies to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • BioSpecifics Technologies's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • BioSpecifics Technologies's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for BioSpecifics Technologies's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are BioSpecifics Technologies's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:BSTC PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $3.35
NasdaqGM:BSTC Share Price ** NasdaqGM (2020-03-27) in USD $51.5
United States of America Biotechs Industry PE Ratio Median Figure of 37 Publicly-Listed Biotechs Companies 15.87x
United States of America Market PE Ratio Median Figure of 2,935 Publicly-Listed Companies 13.38x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of BioSpecifics Technologies.

NasdaqGM:BSTC PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:BSTC Share Price ÷ EPS (both in USD)

= 51.5 ÷ 3.35

15.4x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • BioSpecifics Technologies is good value based on earnings compared to the US Biotechs industry average.
  • BioSpecifics Technologies is overvalued based on earnings compared to the United States of America market.
Price based on expected Growth
Does BioSpecifics Technologies's expected growth come at a high price?
Raw Data
NasdaqGM:BSTC PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 15.4x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
Not available
United States of America Biotechs Industry PEG Ratio Median Figure of 34 Publicly-Listed Biotechs Companies 0.99x
United States of America Market PEG Ratio Median Figure of 2,005 Publicly-Listed Companies 1.03x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for BioSpecifics Technologies, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on BioSpecifics Technologies's assets?
Raw Data
NasdaqGM:BSTC PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $16.96
NasdaqGM:BSTC Share Price * NasdaqGM (2020-03-27) in USD $51.5
United States of America Biotechs Industry PB Ratio Median Figure of 428 Publicly-Listed Biotechs Companies 2.47x
United States of America Market PB Ratio Median Figure of 5,145 Publicly-Listed Companies 1.27x
NasdaqGM:BSTC PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:BSTC Share Price ÷ Book Value per Share (both in USD)

= 51.5 ÷ 16.96

3.04x

* Primary Listing of BioSpecifics Technologies.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • BioSpecifics Technologies is overvalued based on assets compared to the US Biotechs industry average.
X
Value checks
We assess BioSpecifics Technologies's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. BioSpecifics Technologies has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

BSTC Future Performance

 How is BioSpecifics Technologies expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
18.7%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is BioSpecifics Technologies expected to grow at an attractive rate?
  • Unable to compare BioSpecifics Technologies's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare BioSpecifics Technologies's earnings growth to the United States of America market average as no estimate data is available.
  • Unable to compare BioSpecifics Technologies's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:BSTC Future Growth Rates Data Sources
Data Point Source Value (per year)
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 18.7%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 15.7%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 12.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:BSTC Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:BSTC Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2020-12-31 44 1
2020-03-28
NasdaqGM:BSTC Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 38 22 24
2019-09-30 36 20 23
2019-06-30 35 19 22
2019-03-31 34 25 20
2018-12-31 33 18 20
2018-09-30 30 16 17
2018-06-30 28 15 14
2018-03-31 27 9 12
2017-12-31 27 13 11
2017-09-30 27 11 12
2017-06-30 28 13 12
2017-03-31 27 12 12

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if BioSpecifics Technologies is high growth as no earnings estimate data is available.
  • Unable to determine if BioSpecifics Technologies is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:BSTC Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from BioSpecifics Technologies Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:BSTC Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2020-12-31
2020-03-28
NasdaqGM:BSTC Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 3.35
2019-09-30 3.19
2019-06-30 3.03
2019-03-31 2.82
2018-12-31 2.77
2018-09-30 2.29
2018-06-30 1.97
2018-03-31 1.67
2017-12-31 1.58
2017-09-30 1.62
2017-06-30 1.67
2017-03-31 1.67

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if BioSpecifics Technologies will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess BioSpecifics Technologies's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
BioSpecifics Technologies has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

BSTC Past Performance

  How has BioSpecifics Technologies performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare BioSpecifics Technologies's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • BioSpecifics Technologies has delivered over 20% year on year earnings growth in the past 5 years.
  • BioSpecifics Technologies's 1-year earnings growth is less than its 5-year average (22% vs 25.7%)
  • BioSpecifics Technologies's earnings growth has not exceeded the US Biotechs industry average in the past year (22% vs 22%).
Earnings and Revenue History
BioSpecifics Technologies's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from BioSpecifics Technologies Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:BSTC Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 38.19 24.47 9.29 0.59
2019-09-30 36.28 23.30 9.08 0.64
2019-06-30 35.00 22.07 9.33 0.66
2019-03-31 34.00 20.49 9.65 0.71
2018-12-31 32.96 20.05 8.81 0.76
2018-09-30 29.81 16.51 8.07 0.75
2018-06-30 28.16 14.19 7.98 0.97
2018-03-31 26.84 11.96 8.22 1.13
2017-12-31 27.44 11.33 8.54 1.22
2017-09-30 27.36 11.60 8.90 1.27
2017-06-30 27.73 11.94 8.57 1.23
2017-03-31 27.37 11.89 8.16 1.33
2016-12-31 26.25 11.37 7.90 1.33
2016-09-30 25.77 11.11 7.87 1.29
2016-06-30 25.18 10.93 7.74 1.23
2016-03-31 23.71 10.12 7.63 1.04
2015-12-31 22.75 9.62 7.27 1.03
2015-09-30 21.26 8.88 6.73 1.11
2015-06-30 18.97 7.40 6.68 1.09
2015-03-31 16.89 6.22 6.37 1.12
2014-12-31 14.04 4.65 5.81 1.26
2014-09-30 13.47 4.45 5.51 1.28
2014-06-30 12.62 4.24 4.92 1.39
2014-03-31 13.24 4.69 4.67 1.57
2013-12-31 14.43 5.29 5.04 1.48
2013-09-30 13.90 4.66 5.08 1.41
2013-06-30 13.21 3.95 5.39 1.36
2013-03-31 12.54 3.59 5.30 1.30

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • BioSpecifics Technologies has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • BioSpecifics Technologies used its assets more efficiently than the US Biotechs industry average last year based on Return on Assets.
  • BioSpecifics Technologies's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess BioSpecifics Technologies's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
BioSpecifics Technologies has a total score of 2/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

BSTC Health

 How is BioSpecifics Technologies's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up BioSpecifics Technologies's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • BioSpecifics Technologies is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • BioSpecifics Technologies's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of BioSpecifics Technologies's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • BioSpecifics Technologies has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from BioSpecifics Technologies Company Filings, last reported 2 months ago.

NasdaqGM:BSTC Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 124.49 0.00 89.24
2019-09-30 117.00 0.00 81.86
2019-06-30 110.31 0.00 85.28
2019-03-31 102.21 0.00 84.50
2018-12-31 97.59 0.00 80.88
2018-09-30 91.74 0.00 71.81
2018-06-30 86.94 0.00 66.55
2018-03-31 81.84 0.00 61.31
2017-12-31 67.52 0.00 59.31
2017-09-30 64.71 0.00 54.59
2017-06-30 62.10 0.00 51.15
2017-03-31 59.70 0.00 47.87
2016-12-31 56.28 0.00 49.02
2016-09-30 53.22 0.00 49.82
2016-06-30 49.91 0.00 43.57
2016-03-31 47.60 0.00 41.79
2015-12-31 44.81 0.00 33.49
2015-09-30 42.11 0.00 30.93
2015-06-30 37.27 0.00 27.79
2015-03-31 33.67 0.00 23.74
2014-12-31 30.26 0.00 20.71
2014-09-30 26.01 0.00 17.51
2014-06-30 24.36 0.00 16.63
2014-03-31 23.48 0.00 16.91
2013-12-31 22.33 0.00 12.59
2013-09-30 20.45 0.00 11.33
2013-06-30 19.55 0.00 11.98
2013-03-31 18.63 0.00 12.21
  • BioSpecifics Technologies has no debt.
  • BioSpecifics Technologies has not taken on any debt in the past 5 years.
  • BioSpecifics Technologies has no debt, it does not need to be covered by operating cash flow.
  • BioSpecifics Technologies has no debt, therefore coverage of interest payments is not a concern.
X
Financial health checks
We assess BioSpecifics Technologies's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. BioSpecifics Technologies has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

BSTC Dividends

 What is BioSpecifics Technologies's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from BioSpecifics Technologies dividends.
If you bought $2,000 of BioSpecifics Technologies shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate BioSpecifics Technologies's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate BioSpecifics Technologies's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:BSTC Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 65 Stocks 2.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1956 Stocks 2.9%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.9%
United States of America Top 25% Dividend Yield 75th Percentile 5.3%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:BSTC Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2020-12-31
2020-03-28

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as BioSpecifics Technologies has not reported any payouts.
  • Unable to verify if BioSpecifics Technologies's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of BioSpecifics Technologies's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as BioSpecifics Technologies has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess BioSpecifics Technologies's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can BioSpecifics Technologies afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. BioSpecifics Technologies has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

BSTC Management

 What is the CEO of BioSpecifics Technologies's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
J. Buchi
AGE 64
TENURE AS CEO 0.4 years
CEO Bio

Mr. J. Kevin Buchi serves as Director of Dicerna Pharmaceuticals, Inc. since August 16, 2018 and has been its Chairman since January 24, 2019. Mr. Buchi has been Chief Executive Officer of BioSpecifics Technologies Corp. since October 08, 2019. Mr. Buchi has been an Independent Director of Amneal Pharmaceuticals, Inc. since May 4, 2018. Mr. Buchi served as Interim Chief Executive Officer and Interim President of Impax Laboratories, Inc. from December 19, 2016 to March 27, 2017. Mr. Buchi served as the Chief Executive Officer and President of TetraLogic Pharmaceuticals Corporation from August 19, 2013 to December 30, 2016. He served as Corporate Vice President of Global Branded Products at Teva Pharmaceutical Industries Limited from October 2011 to May 2012. He served as the Chief Executive Officer of Cephalon Inc. from December 23, 2010 to October 2011. He served as the Chief Operating Officer of Cephalon Inc. from January 28, 2010 to December 2010. He served as the Chief Financial Officer of Cephalon Inc. from April 1996 to January 28, 2010 and also served as its Principal Accounting Officer until January 28, 2010. He served as the Head of Business Development of Cephalon Inc since 2004. He served as an Executive Vice President of Cephalon Inc. from February 2006 to January 28, 2010. He served as Senior Vice President of Cephalon Inc. from April 1996 to 2006, Controller since March 1991 and held several financial positions. Mr. Buchi served in a number of financial positions at E.I. du Pont de Nemours and Company from 1985 to 1991. He was responsible for Finance, Accounting, Business Development and Information Systems and involved in raising significant financing for Cephalon Inc. He helped and guided Cephalon through several financings, product and company acquisitions and in the development and execution of successful growth strategies. He served positions at PricewaterhouseCoopers. He was a Synthetic Organic Chemist for the Eastman Kodak Company. Mr. Buchi joined Cephalon in March 1991. He has helped guide Cephalon through several financings, product and company acquisitions and in the development and execution of successful growth strategies. He has been Director of Teva Pharmaceuticals Australia Pty Ltd since May 2009 and Chemgenex Pharmaceuticals Ltd since June 2011. He served as Director at Impax Laboratories, Inc. since November 23, 2016 until 2018. He served as a Director of TetraLogic Pharmaceuticals Corporation from August 2013 to December 30, 2016. He served as Director of Alexza Pharmaceuticals Inc. from January 3, 2013 to June 21, 2016. Mr. Buchi served as an Independent Director at EPIRUS Biopharmaceuticals, Inc. since July 2014 until July 25, 2016. He served as an Independent Director of Stemline Therapeutics, Inc. from March 15, 2012 to May 25, 2016. Mr. Buchi served as a Director of Benitec Biopharma Ltd., a NASDAQ listed biotechnology company headquartered in Australia since April 2013. He served as a Non-Executive Director of Mesoblast Limited from December 30, 2010 to May 10, 2012. He served as a Director of Forward Pharma A/S since December 2012 until May 6, 2016. He served as a Director of Celator Pharmaceuticals, Inc. since July 31, 2006, Cephalon Inc. since December 23, 2010 and Teva Pharmaceuticals Australia Pty Ltd since May 2009. He served as a Member of Life Sciences Advisory Board at Safeguard Scientifics, Inc. He served as a Director of Aptose Biosciences Inc. (formerly, Lorus Therapeutics Inc.) since December 2002. He served as a Director of Encysive Pharmaceuticals Inc. from June 23, 2004 to June 2008. He is a Certified Public Accountant. Mr. Buchi holds a BA in Chemistry from Cornell University in 1976 and an MBA Degree in Management from the J.L. Kellogg Graduate School of Management, Northwestern University in 1980.

CEO Compensation
  • Insufficient data for J. to compare compensation growth.
  • Insufficient data for J. to establish whether their remuneration is reasonable compared to companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the BioSpecifics Technologies management team in years:

0.4
Average Tenure
62
Average Age
  • The average tenure for the BioSpecifics Technologies management team is less than 2 years, this suggests a new team.
Management Team

J. Buchi

TITLE
Chief Executive Officer
AGE
64
TENURE
0.4 yrs

Pat Hutchison

TITLE
Chief Financial Officer
AGE
60
TENURE
0.2 yrs

Pat Caldwell

TITLE
Principal Accounting Officer
AGE
57

Ron Law

TITLE
Senior Vice President of Business Development
AGE
66
TENURE
1.3 yrs

Carl Valenstein

TITLE
Corporate Secretary
Board of Directors Tenure

Average tenure and age of the BioSpecifics Technologies board of directors in years:

12.8
Average Tenure
78
Average Age
  • The average tenure for the BioSpecifics Technologies board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

Jenn Chao

TITLE
Independent Chairman of the Board
COMPENSATION
$340K
AGE
49
TENURE
0.4 yrs

Paul Gitman

TITLE
Independent Director
COMPENSATION
$45K
AGE
78
TENURE
30.2 yrs

Michael Schamroth

TITLE
Independent Director
COMPENSATION
$45K
AGE
79
TENURE
15.8 yrs

Toby Wegman

TITLE
Director
COMPENSATION
$22K
AGE
84
TENURE
12.8 yrs

Mark Wegman

TITLE
Director
COMPENSATION
$50K
AGE
69
TENURE
12.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
11. Sep 19 Sell Toby Wegman Individual 09. Sep 19 10. Sep 19 -10,000 $55.23 $-551,677
10. Jun 19 Sell Jennifer Chao Individual 07. Jun 19 07. Jun 19 -459 $58.55 $-26,874
06. Jun 19 Sell Jennifer Chao Individual 04. Jun 19 05. Jun 19 -5,511 $58.01 $-315,543
05. Jun 19 Sell Patrick Caldwell Individual 03. Jun 19 03. Jun 19 -6,000 $58.80 $-352,800
03. Jun 19 Sell Jennifer Chao Individual 29. May 19 29. May 19 -3,313 $60.74 $-201,232
28. May 19 Sell Mark Wegman Individual 24. May 19 24. May 19 -7,800 $61.09 $-476,502
23. May 19 Sell Mark Wegman Individual 22. May 19 22. May 19 -1,200 $63.70 $-76,440
22. May 19 Sell Toby Wegman Individual 21. May 19 21. May 19 -5,500 $64.67 $-352,353
22. May 19 Sell Mark Wegman Individual 21. May 19 21. May 19 -6,000 $64.04 $-384,236
17. May 19 Sell Paul Gitman Individual 15. May 19 15. May 19 -5,000 $65.83 $-329,150
X
Management checks
We assess BioSpecifics Technologies's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. BioSpecifics Technologies has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

BSTC News

Simply Wall St News

A Look At BioSpecifics Technologies Corp.'s (NASDAQ:BSTC) Exceptional Fundamentals

BSTC is a company with great financial health as well as a an impressive track record of performance. … For those interested in understanding where the figures come from and want to see the analysis, take a look at the report on BioSpecifics Technologies here.Flawless balance sheet with proven track record BSTC delivered a bottom-line expansion of 56% in the prior year, with its most recent earnings level surpassing its average level over the last five years. … BSTC has plenty of financial flexibility, without debt obligations to meet in the short term, as well as the headroom to raise debt should it need to in the future.

Simply Wall St -

Do You Know What BioSpecifics Technologies Corp.'s (NASDAQ:BSTC) P/E Ratio Means?

The formula for P/E is: Price to Earnings Ratio = Price per Share ÷ Earnings per Share (EPS) Or for BioSpecifics Technologies: P/E of 19.39 = $58.73 ÷ $3.03 (Based on the year to June 2019.) Is A High Price-to-Earnings Ratio Good? … NasdaqGM:BSTC Price Estimation Relative to Market, August 18th 2019 Its P/E ratio suggests that BioSpecifics Technologies shareholders think that in the future it will perform about the same as other companies in its industry classification. … How Does BioSpecifics Technologies's Debt Impact Its P/E Ratio?

Simply Wall St -

BioSpecifics Technologies Corp. (NASDAQ:BSTC) Insiders Have Been Selling

So we'll take a look at whether insiders have been buying or selling shares in BioSpecifics Technologies Corp. … As Peter Lynch said, 'insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.' See our latest analysis for BioSpecifics Technologies The Last 12 Months Of Insider Transactions At BioSpecifics Technologies In the last twelve months, the biggest single sale by an insider was when the insider, Thomas Wegman, sold US$3.3m worth of shares at a price of US$51.89 per share. … While insider selling is not a positive sign, we can't be sure if it does mean insiders think the shares are fully valued, so it's only a weak sign.

Simply Wall St -

How Does Investing In BioSpecifics Technologies Corp. (NASDAQ:BSTC) Impact The Volatility Of Your Portfolio?

Beta is a widely used metric to measure a stock's exposure to market risk (volatility). … See our latest analysis for BioSpecifics Technologies What does BSTC's beta value mean to investors? … If this beta value holds true in the future, BioSpecifics Technologies shares are likely to rise more than the market when the market is going up, but fall faster when the market is going down.

Simply Wall St -

Does BioSpecifics Technologies (NASDAQ:BSTC) Deserve A Spot On Your Watchlist?

Are BioSpecifics Technologies Insiders Aligned With All Shareholders? … As a result, I'm encouraged by the fact that insiders own BioSpecifics Technologies shares worth a considerable sum. … For growth investors like me, BioSpecifics Technologies's raw rate of earnings growth is a beacon in the night.

Simply Wall St -

Did Business Growth Power BioSpecifics Technologies's (NASDAQ:BSTC) Share Price Gain of 128%?

One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price. … Over half a decade, BioSpecifics Technologies managed to grow its earnings per share at 31% a year. … NasdaqGM:BSTC Past and Future Earnings, June 20th 2019 We know that BioSpecifics Technologies has improved its bottom line lately, but is it going to grow revenue?

Simply Wall St -

Is BioSpecifics Technologies Corp.'s (NASDAQ:BSTC) 18% ROE Better Than Average?

While some investors are already well versed in financial metrics (hat tip), this article is for those who would like to learn about Return On Equity (ROE) and why it is important. … One way to conceptualize this, is that for each $1 of shareholders' equity it has, the company made $0.18 in profit. … Return on Equity = Net Profit ÷ Shareholders' Equity

Simply Wall St -

Is BioSpecifics Technologies's Share Price Gain Of 195% Well Earned?

By comparing earnings per share (EPS) and and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time. … During five years of share price growth, BioSpecifics Technologies achieved compound earnings per share (EPS) growth of 37% per year. … The EPS growth is more impressive than the yearly share price gain of 24% over the same period.

Simply Wall St -

Need To Know: BioSpecifics Technologies Corp. (NASDAQ:BSTC) Insiders Have Been Selling Shares

We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. … It is perfectly legal for company insiders, including board members, to buy and sell stock in a company. … As Peter Lynch said, 'insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.'.

Simply Wall St -

Is BioSpecifics Technologies Corp. (NASDAQ:BSTC) Overpaying Its CEO?

This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. … View our latest analysis for BioSpecifics Technologies? … How Does Thomas Wegman's Compensation Compare With Similar Sized Companies?

Simply Wall St -

BSTC Company Info

Description

BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for various indications in the United States and internationally. The company offers injectable collagenase for the treatment of Dupuytren’s contracture and Peyronie’s disease under the XIAFLEX or Xiapex brands. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, plantar fibromatosis, and human lipoma, as well as uterine fibroids. In addition, the company engages in the development of other clinical indications for which collagenase injection has been tested, such as keloids, hypertrophic scars, scarred tendons, glaucoma, herniated intervertebral discs, and as an adjunct to vitrectomy. BioSpecifics Technologies Corp. has a development and license agreement with Endo Global Ventures. The company was founded in 1957 and is headquartered in Wilmington, Delaware.

Details
Name: BioSpecifics Technologies Corp.
BSTC
Exchange: NasdaqGM
Founded: 1957
$377,952,985
7,336,756
Website: http://www.biospecifics.com
Address: BioSpecifics Technologies Corp.
Delaware Corporate Center II,
2 Righter Parkway,
Wilmington,
Delaware, 19803,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM BSTC Common Stock Nasdaq Global Market US USD 14. Nov 1991
BST 1B3 Common Stock Boerse-Stuttgart DE EUR 14. Nov 1991
Number of employees
Current staff
Staff numbers
7
BioSpecifics Technologies employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/28 01:02
End of day share price update: 2020/03/27 00:00
Last estimates confirmation: 2020/03/17
Last earnings filing: 2020/03/16
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.